Moreover, regarding the treatment outcome, the downregulation of HSPB2 and HSPB3 genes in early tumors is significantly associated with BlCa recurrence in NMIBC patients, whereas increased expression of HSPB2 (and likely HSPB3) genes likely correlate with decreased overall survival in advanced disease stages (muscle-invasive tumors). The gene discussed is HSPB3; the disease is bladder transitional cell carcinoma.